Company Profile

Kubanda Cryotherapy Inc
Profile last edited on: 9/13/22      CAGE: 88UR3      UEI: VKVEU52JTWK6

Business Identifier: Affordable, acccessible and reliable cyroblation
Year Founded
2019
First Award
2021
Latest Award
2021
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3600 Clipper Mill Road Suite 310
Baltimore, MD 21211
Location: Single
Congr. District: 03
County: Baltimore City

Public Profile

Kubanda Cryotherapy Inc is structured around offering minimally invasive, non-surgical treatment for lumps, bumps, and cancers in pets. The firm, for example, provides minimally invasive cryotherapy treatment as an alternative to surgical resections. Cryoablation kills cancer cells through the formation of intracellular ice crystals. Kubanda's custom-designed cryosystem consists of a cryoprobe and a gas-control module made to modulate temperature. Together, this system creates freezing cycles proven to shrink and kill tumors. During surgery, the animal's skin is protected against the cold while the probe is inserted into the tumor. Careful monitoring of the tumor temperature while undergoing freeze cycles allows a successful procedure in which the tumors are killed.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2021 1 NIH $399,999
Project Title: Low Cost Carbon Dioxide-Based Cryoablation for Breast Cancer Treatment in Low Resource Settings

Key People / Management

  Bailey Surtees -- Co-Founder and CEO

  Nicholas Durr -- Co-Founder

  Clarisse Hu -- CTO and Co-Founder

Company News

There are no news available.